Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report.
Growing evidence points toward the key role of angiogenesis in ovarian cancer. Granulosa cell tumor (GCT) does not seem to be an exception. Recent studies reporting the use of bevacizumab, a monoclonal antibody against the vascular epithelial growth factor, in recurrent GCT have shown encouraging results in terms of both symptoms control and response rate. This study presented the case of an adult-type GCT treated with neoadjuvant bevacizumab. To the best of the Authors' knowledge, this is the first report describing the use of an anti-angiogenic agent as neoadjuvant therapy in GCT. A further discussion on the results of this study and those previously published is also given.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. nibarren@uc.cl
Nicanor I
NI
Barrena Medel
Thomas J
TJ
Herzog
Jason D
JD
Wright
Sharyn N
SN
Lewin
D000328:Adult; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005260:Female; D006106:Granulosa Cell Tumor / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab